Tyra oral dabogratinib posts 79% ORR and 64% CR in Phase 2
Tyra Biosciences said oral dabogratinib in Phase 2 LG IR NMIBC showed favorable safety and strong efficacy: 79% ORR and 64% CR at 60 mg QD, supporting Phase 3 advancement and higher-dose exploration.
Initial Phase 2 results for oral dabogratinib in LG IR NMIBC showed favorable safety and strong efficacy, with 79% ORR and 64% CR at 60 mg QD. The data support moving to Phase 3 and evaluating higher doses for patients with greater tumor burden.